Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Right now we have entered into a sideways trading pattern until the next catalyst.....
Loading zone!
We will NOT see this PPS again after the next leg up. Period
It was news, from the 28th related to EPA certification on one of their engines! Shhh lol
Been watching here for a very long time. Just finally took a position. This position holds the BEST potential value of all that I hold IMO!!! Glta
Sweet! Love the website... Imagine if these B&B's were available through RCI and they started selling timeshares! Can you say..... CHA CHA CHING!!
My thoughts EXACTLY!!
If Donald Trump gets elected, we WILL see this legalized at the Federal level!
Took a position here today, GLTA!
Added, looking for bottom! GLTA
8K Filing Just Released!
http://ih.advfn.com/p.php?pid=nmona&article=68287067&symbol=ETRM
Looks like we have a runner! BOOM
Some nice movement is starting! Getting excited
Print
Alert
Graphene 3D Lab (TSXV:GGG)
Intraday Stock Chart
Today : Monday 24 August 2015
Click Here for more Graphene 3D Lab Charts.
TSX-V: GGG, OTCQB: GPHBF
NEW YORK, NY, Aug. 24, 2015 /CNW/ - Graphene 3D Lab Inc. (TSX-V: GGG) (OTCQB: GPHBF) ("Graphene 3D") Board Chairman, Jason Martin is pleased to announce a new executive leadership structure. Ian Klassen, Company Director, will be appointed President and Chief Operating Officer. Elena Polyakova will immediately serve as Co-Chief Executive Officer with Daniel Stolyarov.
"Since the launch of our conductive filament in March this year, the Company has seen strong sales demand and interest from several manufacturing partners to work with us on future polymer projects outside of the 3D printing industry," said Mr. Martin. "We have bolstered the management team to ensure our founders have the support they need to maximize future opportunities for Graphene 3D."
Mr. Klassen has 25 years of experience in public company management, public relations, government affairs and entrepreneurialism. He has extensive experience in public company administration, finance, government/legislative policy, media relationship strategies and project management. He has spent many years leading North American mineral exploration companies and sits on the Board of Directors of both private and public companies. Previous to his management activities within private and public companies, Mr. Klassen held a variety of positions within federal Canadian politics including; Senior Political Advisor to the Minister of State (Transportation); and Chief of Staff, Office of the Speaker of the Canadian House of Commons.
Mr. Klassen graduated with an undergraduate Honours Degree from the University of Western Ontario in 1989. In 1992, Mr. Klassen received the Commemorative Medal for the 125th Anniversary of the Confederation of Canada in recognition of his significant contribution to his community and country.
Martin reflected on the Company's first full year of operation since listing on the TSX-V in August of 2014. "It has been a year of significant accomplishments for our Company which include: filing a patent for the world's first 3D printed graphene battery; launching the sale of conductive filaments; and establishing and expanding our filament production facilities. We have several other projects in our development pipeline."
"Our company is rapidly moving from principally an R&D focus to creating a variety of revenue models", added Elena Polyakova, Co-Chief Executive Officer. "We have established a revenue channel with our functional 3D filaments, now we are expanding our revenue opportunities as a leading graphene manufacturer. The recent acquisition of Graphene Labs (see August 12 new release), will allow our work with advanced material polymers to expand into markets beyond the 3D printing sector. We look forward to Ian joining our management team to work with us in bringing these new revenue opportunities to fruition".
As well, the Company wishes to announce that, subject to regulatory approval and in accordance with its shareholder approved stock option plan, it has granted incentive stock options to Mr. Klassen to purchase up to 200,000 common shares exercisable on or before August 24, 2020 at a price of $0.69 per share.
About Graphene 3D
Graphene 3D Lab is in the business of developing, manufacturing, and marketing proprietary graphene-based nanocomposite materials for various types of 3D printing, including fused filament fabrication. The Company is also involved in the design, manufacture, and marketing of 3D printers and related products for domestic and international customers.
The Graphene 3D Lab facility is located in Calverton, NY and is equipped with material processing and analytical equipment. The company has four US patent applications pending for its technology. For more information on Graphene 3D Lab, Inc., visit www.graphene3dlab.com.
FORWARD LOOKING INFORMATION
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE Graphene 3D Lab Inc.
Copyright 2015 Canada NewsWire
More GGG Messages
Finally took a position here today!
The I couldn't resist after reviewing the chart and today's trading!
GLTA!
BRLX is building their pipeline!
Great things on the horizon. Check out the board for some DD I recently posted
Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following BL-8040 Update
http://www.streetinsider.com/dr/news.php?id=10515886
BioLineRx's (BLRX) CEO Kinneret Savitsky on Q2 2015 Results - Earnings Call Transcript $BLRX
http://www.seekingalpha.com/article/3455346
Looks like we may be starting a reversal bounce off the bottom!
BioLineRx reports Q2 ; Phase 2 BL-8040 data for AML in Q4; meeting with FDA in October to discuss BL-8040 for stem cell mobilization treatment
Font size: A | A | A
7:11 AM ET 8/20/15 | Briefing.com
RELATED QUOTES
4:00 PM ET 8/19/15
Symbol Last % Chg
BLRX
1.51 0.00%
Real time quote.
Q2 EPS ($0.09) vs. ($0.12) last year. "We expect some very exciting milestones for our BL-8040 oncology platform in the coming few months. First, we expect to report top-line data, including response rates, from our Phase 2 clinical study for treating relapsed/refractory AML in the fourth quarter of 2015, following the highly encouraging results to date we reported from the dose escalation stage of this study. Additionally, we presented positive safety and efficacy results from our Phase 1 study of BL-8040 as a novel stem cell mobilization treatment at the European Hematology Association conference in June, which supported the use of BL-8040 as a single-agent, single-injection, one-day regimen for the collection and transplantation of stem cells. This is a major improvement over currently available procedures, and the superior composition of the collected cells may offer the potential for better quality grafts and improved transplant outcomes. We look forward to meeting with the FDA in October to discuss the next steps in the clinical development of this program. Based on the outcome of the meeting, we would expect to initiate a Phase 2 study as early as the first quarter of 2016."
Added some today myself too....
HyperSolar Sees Growing Market for Hydrogen Powered Aircraft
Flight of First Hydrogen Fuel Cell-Powered Unmanned Aerial Vehicle and Recent Patent Awarded to Airbus for Hydrogen-Powered Hypersonic Passenger Plane Represent Important Milestones for the Use of Hydrogen in Aeronautics
SANTA BARBARA, CA--(Marketwired - August 18, 2015) - HyperSolar, Inc. (OTCQB: HYSR), the developer of a breakthrough technology to produce renewable hydrogen using sunlight and water, today commented on recent news from both a well-known commercial airplane manufacturer, as well as researchers who successfully executed the first hydrogen fuel cell-powered unmanned aerial vehicle flight in the Middle East.
A group of researchers at the Department of Mechanical Engineering at the American University of Sharjah (AUS) conducted the fuel cell powered flight, taking place in the United Arab Emirate and Gulf Cooperation Council regions. The plane cruised comfortably during flight duration of approximately ten minutes, powered only by a Proton Exchange Membrane hydrogen fuel cell (PEMFC). The team will now look to pursue further tests related to payload capacity, endurance, and the ability to fly autonomously.
In the commercial space, the U.S. Patent and Trademark Office just awarded a patent to Airbus for a hypersonic passenger plane. The jet is designed to utilize rocket engines to propel to supersonic speeds, where hydrogen-powered wing mounted ramjets would engage to propel the jet to its destination. While still under development, the plane could potentially fly from New York to London in an hour, and from Paris to Tokyo in under three hours.
"While these technologies are not yet available, we see great potential for the use of hydrogen fuel cell technology in the aeronautics space," said Tim Young, CEO of HyperSolar. "These recent news events have occurred due to the global commitment to hydrogen fuel innovation spanning industries including consumer automobile, transportation, industrial, and more. It is our belief that the R&D efforts surrounding new hydrogen technologies will result in an increased demand for hydrogen fuel, one that HyperSolar can potentially leverage upon its own technology's commercialization."
HyperSolar's research is centered on developing a low-cost and submersible hydrogen production particle that can split water molecules under the sun, emulating the core functions of photosynthesis. Each particle is a complete hydrogen generator that contains a novel high voltage solar cell bonded to chemical catalysts by a proprietary encapsulation coating. A video of an early proof-of-concept prototype can be viewed at http://hypersolar.com/application.php.
About HyperSolar, Inc.
HyperSolar is developing a breakthrough, low cost technology to make renewable hydrogen using sunlight and any source of water, including seawater and wastewater. Unlike hydrocarbon fuels, such as oil, coal and natural gas, where carbon dioxide and other contaminants are released into the atmosphere when used, hydrogen fuel usage produces pure water as the only byproduct. By optimizing the science of water electrolysis at the nano-level, our low cost nanoparticles mimic photosynthesis to efficiently use sunlight to separate hydrogen from water, to produce environmentally friendly renewable hydrogen. Using our low cost method to produce renewable hydrogen, we intend to enable a world of distributed hydrogen production for renewable electricity and hydrogen fuel cell vehicles. To learn more about HyperSolar, please visit our website at www.hypersolar.com.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein, and while expected, there is no guarantee that we will attain the aforementioned anticipated developmental milestones. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
Press Contact:
Eric Fischgrund
FischTank Marketing and PR
Email contact
(MORE TO FOLLOW) Dow Jones Newswires
August 18, 2015 03:30 ET (07:30 GMT)
I'm going to predict that there will be an announcement regarding HYSR achieving their target voltage right around the time of this conference. Fits right into the voltage progression timeline...
Form 4 just issued. CEO/president bought 10,000 more shares.
I was just about to post this, nice DD!
Things are building, happy to be here NOW!!
BioLineRx Announces Initiation of Phase 2b Trial for Novel
AML Consolidation Treatment
- Phase 2b study, as consolidation treatment for AML patients responding to
standard induction treatment, will enroll up to 194 patients, randomized
in 1:1 ratio, at up to 25 sites in Germany -
- Study is first of three additional clinical studies for BL-8040 platform
expected to commence during 2015 -
Tel Aviv, Israel, August 17, 2015 - BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a Phase 2b trial for BL-8040 as a novel consolidation treatment for acute myeloid leukemia (AML). The Phase 2b study will examine BL-8040 as part of a second stage treatment, termed consolidation therapy, to improve outcomes for AML patients who have achieved remission after the standard initial treatment regimen, known as induction therapy. The consolidation therapy is aimed at eliminating the minimal residual disease left in the bone marrow after induction therapy that can lead to relapse. This study is the first of three clinical studies in additional indications for BL-8040 which BioLineRx plans to commence during 2015, thus significantly expanding its unique BL-8040 oncology platform.
Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx, stated, “The majority of high-risk AML patients achieving first complete remission relapse within one year, despite the current standard consolidation therapy. Patients with AML relapse have a poor prognosis despite further therapy, and less than 10% of these patients are cured by conventional therapy. Leukemic stem cells that are dormant in the bone marrow are presumed to be a major reason for AML relapse. Based on the pre-clinical and clinical data accumulated to date, BL-8040 is anticipated to boost the efficacy of consolidation therapy due to its dual mechanism of action. Firstly, BL-8040 induces mobilization of leukemic cells from the bone marrow, which enhances the cytotoxic effects of chemotherapy, and secondly, it possesses anti-leukemic pro-apoptotic properties that help eliminate AML cells directly. Based on positive results from our ongoing phase 2 clinical trial for BL-8040, which show substantial mobilization of AML cells from the bone marrow to the peripheral blood, as well as robust induction of AML cell apoptosis, we believe BL-8040 will be a promising addition to consolidation therapy for AML patients.”
Dr. Savitsky added, “In addition to initiation of the Phase 2b AML consolidation study, we are eagerly looking forward to the top-line results from our ongoing Phase 2 study of BL-8040 for treating relapsed and refractory AML patients, which we expect in the fourth quarter of 2015. We also look forward to the next stages of development for BL-8040 as a novel stem cell mobilization treatment, after its recent successful completion of a Phase 1 trial. Finally, we are also excited about the anticipated initiation of clinical studies for BL-8040 in two additional indications over the next few months, thus further expanding and enhancing the potential of our oncology platform.”
The Phase 2b trial, which is conducted in collaboration with the University of Halle as sponsor and with the participation of two large leukemia study groups in Germany, is a double-blind, placebo-controlled, randomized, multi-center study aimed at assessing the efficacy of BL-8040 in addition to standard consolidation therapy in AML patients. The primary endpoint of the study is to compare the relapse free survival (RFS) time in AML subjects in their first remission during a minimum follow-up time of 18 months after randomization. In addition, pharmacodynamic measurements will be conducted in order to assess the minimal residual disease, and biomarker analyses will be performed to identify predictors of BL-8040 response. The study will enroll up to 194 patients at up to 25 sites in Germany. AML patients between 18 and 75 years of age with documented first remission will be randomized in a 1:1 ratio to receive high dose Cytarabine, either with BL-8040 or with a matching placebo, as consolidation therapy.
About BL-8040
BL-8040 is a clinical-stage drug candidate for the treatment of acute myeloid leukemia, as well as other hematological indications. It is a short peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis (growth of new blood vessels in the tumor), metastasis (spread of the disease to other organs or organ parts) and cell survival. CXCR4 is over-expressed in more than 70% of human cancers and its expression often correlates with disease severity. In a Phase 1/2, open-label, dose escalation, safety and efficacy clinical trial in 18 multiple myeloma patients, BL-8040, when combined with G-CSF, demonstrated an excellent safety profile at all doses tested and was highly effective in the mobilization of hematopoietic stem cells and white blood cells from the bone marrow to the peripheral blood. Additionally, in a Phase 1 stem-cell mobilization study in healthy volunteers, BL-8040 as a single agent was safe and well tolerated at all doses tested and resulted in efficient stem-cell mobilization and collection in all study participants. Importantly, the results of this study support the use of BL-8040 as one-day, single-dose collection regimen, which is a significant improvement upon the current standard of care.
BL-8040 also mobilizes cancer cells from the bone marrow and may therefore sensitize these cells to chemo- and bio-based anti-cancer therapy. Importantly, BL-8040 has also demonstrated a direct anti-cancer effect by inducing apoptosis. Pre-clinical studies show that BL-8040 inhibits the growth of various tumor types including multiple myeloma, non-Hodgkin's lymphoma, leukemia, non-small cell lung carcinoma, neuroblastoma and melanoma. BL-8040 significantly and preferentially stimulated apoptotic cell death of malignant cells (multiple myeloma, non-Hodgkin's lymphoma and leukemia). Significant synergistic and/or additive tumor cell killing activity has been observed in-vitro and in-vivo when tumor cells were treated with BL-8040 together with Rituximab, Bortezomib, Imatinib, Cytarabine and the FLT-3 inhibitor AC-220 (in NHL, MM, CML, AML, and AML-FLT3-ITD models, respectively). In addition, the current Phase 2 clinical trial in AML patients has demonstrated robust mobilization and apoptosis of cancer cells. BL-8040 was licensed by BioLineRx from Biokine Therapeutics and was previously developed under the name BKT-140.
About Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. According to the American Cancer Society, approximately 19,000 new cases of AML were diagnosed in the United States in 2014, and the median age of AML patients was 67 years old. The first treatment line for patients with AML includes a combination of chemotherapy drugs and is called induction treatment. The median survival for AML patients receiving induction chemotherapy is less than two years, with shorter survival for patients over the age of 60 or for those with certain gene or chromosome aberrations. Due to relapsed or refractory disease (where the disease is not responsive to standard treatments), the overall five-year survival rate for AML is between 10 and 40 percent.
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for acute myeloid leukemia (AML), and has successfully completed a Phase 1 study in stem cell mobilization; BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study; and BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria).
In December 2014, BioLineRx entered into a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates. The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept for potential future licensing by Novartis.
For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases, and events. BioLineRx’s IR app is available on the iTunes App Store as well as the Google Play Store.
Various statements in this release concerning BioLineRx’s future expectations, including specifically those related to the development and commercialization of BL-8040, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2015. In addition, any forward-looking statements represent BioLineRx’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.
Contact:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
jdrumm@tiberend.com
+1-212-375-2664
Andrew Mielach
amielach@tiberend.com
+1-212-375-2694
or
Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipihai5@gmail.com
Took a position here today, GLTA!
I'm here too
Waiting patiently
Agreed
This stock is WAY under the radar.
More like sonar lol
This is where I want to be! How often does one get to invest at the ground level of an emerging market?
Remember, Graphene is the next mericle molecule. This company owns the whole friggin' Graphene superstore
Mikey likes it...
Well worth the wait. Happy to be an investor in the infancy stages of Graphene development!
After all, it is the next "mericle molecule"!!
It would be foolish to look away now. Big things are in the horizon!!!
Any way to find out how long trading will be suspended for?
VANCOUVER and NEW YORK, NY , Aug. 12, 2015 /CNW/ - Graphene 3D Lab Inc. (GGG.V) (GPHBF) ("Graphene 3D" or the "Company") announces that it has entered into a non-arm's length share exchange agreement dated August 12, 2015 (the "SEA") to acquire all of the issued and outstanding shares of Graphene Laboratories Inc. ("GLI"). GLI is incorporated under the laws of the Commonwealth of Massachusetts , and is controlled and managed by Daniel Stolyarov and Elena Polyakova , insiders of Graphene 3D. GLI is active in the business of the manufacture and worldwide distribution of nanocarbon and graphene products. GLI is in the midst of completing its audited financial statements. For the last fiscal year ending December, 2014, GLI recorded annual revenues of in excess of USD $1,000,000 and was cash flow positive. Moreover, GLI has no material debt, and only trade creditors.
Graphene Laboratories Inc., a leader in manufacturing and retailing of graphene and advanced materials owns the Graphene Supermarket®, www.graphene-supermarket.com, a leading supplier of such products to customers around the globe. Graphene Laboratories client list is comprised of more than 8,000 customers worldwide, including nearly every Fortune 500 tech company and major research university. Some notable clients are: NASA, Ford Motor Co., GE, Apple, Xerox, Samsung, Harvard University , IBM and Stanford University.
Graphene Laboratories also holds a provisional patent relating to the manufacture and processing of graphene. In its most pure form, graphene is a single atomic layer of carbon atoms. Graphene is currently available in the market at various grades, with performance characteristics such as mechanical strength, and conductivity improving with fewer atomic layers. Graphene Laboratories patented manufacturing process provides proof of concept to allow for a low-energy, chemical-free manufacture designed to achieve high-grade graphene material at a projected industry leading low cost. Graphene Laboratories has begun planning on a two-phased development program to advance this manufacturing process from bench-top prototype to a large-scale manufacturing operation.
In addition to the retail offering of graphene products, GLI offers analytical services, prototype development and consulting. The addition of GLI's business and graphene product lines will complement and expand the Company's existing business of research, development and production of polymer nanocomposite graphene-based filaments for fused filament fabrication in 3D printers. Graphene Laboratories will operate as a wholly-owned subsidiary of Graphene 3D Lab.
Pursuant to the SEA, the Company will acquire all of the issued and outstanding common shares of GLI by the issuance of up to 3.8 million common shares (the "Exchanged Shares") of the Company (representing approximately 8% of the then total issued shares) to the shareholders of GLI (the "Share Exchange"). A total of 345,500 Exchanged Shares will be issued at closing with a four month and a day hold restriction from the date of closing (the "Closing Date"), a further 600,000 Exchanged Shares will be issued at closing and made subject to automatic releases every 6 months over the next 36 months from the Closing Date. The balance of the 2,854,500 Exchanged Shares will be issued on the basis of one share for every $0.60 in cumulative cash flow generated from the operations of GLI over up to the next 5 fiscal years of the Company. The terms of the Share Exchange are subject to confirmation by a fairness opinion prepared by an independent business valuator, an audit of GLI's financial statements, the approval of the independent directors of the Company, and the acceptance for filing by the TSX Venture Exchange.
Citrus County Real Estate
randymorehouse.realtor Sponsor
?
Daniel Stolyarov , a director, President & CEO of the Company, and Elena Polyakova , a director and COO of the Company each currently own 7,161,212 common shares of the Company (representing 16.5% of the issued shares each). Upon completion of the SEA and assuming the issuance of all Exchanged Shares, Daniel Stolyarov will own an additional 1,689,250 common shares of the Company (or then hold a total of 8,850,462 shares, representing 18.8% of the total issued shares), and Elena Polyakova will own an additional 1,765,250 common shares of the Company (or then hold a total of 8,926,462 shares, representing 18.9% of the total issued shares), which they intend to hold for investment purposes.
There will be no change in the board of directors of the Company, but Elena Polyakova will be appointed the Co-CEO, together with Daniel Stolyarov , the current President & CEO of the Company.
About Graphene 3D
Graphene 3D is BC company whose common shares are listed on the TSX Venture Exchange, which owns all of the issued and outstanding shares of Graphene 3D Lab (U.S.) Inc. ("Graphene US"), a private Delaware corporation, organized on September 3 , 2013. Graphene US is in the business of developing, manufacturing, and marketing proprietary polymer nanocomposite graphene-based materials for various types of 3D printing, including fused filament fabrication as well as the design, manufacture and marketing of three-dimensional printers and products for worldwide customers, including in the aerospace and automotive industries, manufacturers of medical prosthetics and the military. Graphene 3D currently has four US patent applications pending for its technology. For more information on Graphene 3D, visit www.graphene3dlab.com
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company's current expectations. When used in this press release, the words "estimate", "project", "projected", "low-cost", "low-energy", "chemical-free", "fewer", "belief", "anticipate", "intend", "expect", "plan", "predict", "may" or "should" and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release includes information relating to the Transaction (including the anticipated date which the Company's common shares will commence trading on the Exchange). Such statements and information reflect the current view of the Company with respect to risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.
Don't Pay Your Insurance Until You Read This
Auto-Insurance-Discounts Sponsor
?
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with the completion of the Transaction and matters relating thereto; and risks associated with the marketing and sale of securities, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors with certain other projects, and the volatility of the Company's common share price and volume. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.
There are a number of important factors that could cause the Company's actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others, risks related to Graphene 3D's proposed business such as failure of the business strategy, stable supply prices, demand and market prices for 3D printing products, and government regulation; risks related to Graphene 3D's operations, such as additional financing requirements and access to capital, reliance on key and qualified personnel, insurance, competition, intellectual property and reliable supply chains; risks related to Graphene 3D and its business generally such as potential exposure to tax under Canadian and US income tax laws, laws and regulations relating to cross-border mergers and acquisitions, infringement of intellectual property rights, product liability, environmental protection, currency exchange rates and conflicts of interest.
The Company cautions that the foregoing list of material factors is not exhaustive. When relying on the Company's forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company has assumed a certain progression, which may not be realized. It has also assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. While the Company may elect to, it does not undertake to update this information at any particular time.
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE Graphene 3D Lab Inc.
Contact:
Commercial Inquiries: Daniel Stolyarov, President & Chief Executive Officer, Telephone: (631) 405-5116, Email: daniel.stolyarov@graphene3Dlab.com; Media Inquiries: Kristie Galvani, Rubenstein Public Relations, Telephone: (212) 843-9205, Email: KGalvani@rubensteinpr.com; Investor Inquiries: Paul Thomson, Investor Relations Coordinator, Telephone (631) 405-5114, Email: investors@graphene3Dlab.com
At least the halt is by request of the company, makes me feel a tiny bit better... Kinda sorta probably maybe lol
I follow this company on Facebook
They posted an article on 3d printing 7 hours ago
Hopefully it's a "sign"
May be wishful thinking, but I'm hoping for a fat juicy Graphene 3d printer announcement!
The suspense here is gettinto me, ugh lol
Fingers crossed here!
Been adding often for a while now
The suspense is building...
New Product - Polymaker PolyMax PLA, 1.75 mm, 750g
http://www.blackmagic3d.com/product-p/polymax-pla-175.htm?hash=9dfe3629-885c-475f-a3ec-a711e71230b7
The Possibilities of 3D Printing: It’s Only the Beginning
http://www.rdmag.com/articles/2015/06/possibilities-3d-printing-its-only-beginning?hash=b8c85520-f1a8-4382-bac7-ef964e1a7c66
Yep, it's official!
Galena Biopharma Launches Zuplenz(R) (ondansetron) Oral Soluble Film
Jul 29, 2015 07:05:00 (ET)
Galena Biopharma Launches Zuplenz(R) (ondansetron) Oral Soluble Film
-- Zuplenz is indicated for the prevention of chemotherapy-induced nausea
and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and
post-operative nausea and vomiting (PONV)
-- Novel, oral soluble film technology provides convenient delivery and key
patient benefits
PORTLAND, Ore., July 29, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the product launch for Zuplenz(R) (ondansetron) Oral Soluble Film in the United States.
Zuplenz is now available nationwide and is supplied in both 4 mg and 8 mg strengths. Zuplenz is clinically bioequivalent to ondansetron orally disintegrating tablets (ODT) with a safety profile equivalent to ondansetron. The novel, PharmFilm(R) oral soluble film technology utilized by Zuplenz provides for convenient delivery and several key patient benefits including:
-- Rapidly dissolves in the mouth in about 10 seconds
-- Eliminates the burden of swallowing pills during emesis and in cases of
oral irritation
-- Does not require water to administer
-- Pleasant peppermint flavor with no gritty aftertaste
-- Non-sedating
"Ondansetron is the gold-standard treatment option for patients suffering from nausea and vomiting due to chemotherapy, radiation treatments, and surgical procedures; and, we believe the unique and innovative product attributes of Zuplenz will be a valuable treatment option for patients and physicians to relieve these debilitating side-effects," said Mark W. Schwartz, Ph.D., President and Chief Executive Officer. "With the launch of Zuplenz, we will leverage our existing commercial infrastructure including our outsourced Galena Patient Services (GPS) program to work directly with the patient, prescriber, insurance provider, and pharmacy to help guide the process of getting the patient their medication once prescribed by the physician."
Zuplenz is approved in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved for moderately emetogenic CINV in pediatric patients four years and older.
The active pharmaceutical ingredient in Zuplenz, ondansetron, is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. The National Comprehensive Cancer Network (NCCN) 2014 guidelines recommend the use of ondansetron in patients with highly and moderately emetogenic cancer chemotherapy-induced and radiotherapy-induced nausea and vomiting. Ondansetron belongs to a class of medications called serotonin 5-HT(3) receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. According to data from both IMS and Wolters Kluwer, the branded 5-HT(3) market exceeded $1 billion in the U.S. in 2014. The product was licensed from MonoSol Rx, LLC, the developer of the oral soluble film technology, PharmFilm(R) , and manufacturer of the product.
About Zuplenz(R) (ondansetron) Oral Soluble Film
Zuplenz(R) (ondansetron) Oral Soluble Film is approved by the U.S. Food and Drug Administration (FDA) in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved for moderately emetogenic CINV in pediatric patients four years and older. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation.
Zuplenz utilizes the proprietary PharmFilm(R) technology as an oral soluble film that dissolves on the tongue in about 10 seconds. This rapidly dissolving film eliminates the burden of swallowing pills during periods of emesis and in cases of oral irritation, potentially increasing patient adherence. Zuplenz is supplied in both 4 mg and 8 mg ondansetron strengths with clinical bioequivalence to ondansetron orally disintegrating tablets (ODT) and a safety profile equivalent to ondansetron. For more information on Zuplenz, please visit www.Zuplenz.com.
About Chemotherapy-, Radiation- and Post Operative-Induced Nausea and Vomiting
It is estimated that up to 90% of patients receiving chemotherapy experience CINV. CINV patients ranked nausea and vomiting among the most distressing and severe symptoms associated with chemotherapy, and CINV has shown a strong negative impact on social, cognitive, and physical functioning for these patients.
Up to 80% of patients undergoing radiotherapy will experience RINV, and patients experiencing RINV report lower quality of life, reduced physical capacity, more anxiety, and depressed moods. Importantly, if RINV is not effectively treated, it may cause patients to drop out of their radiotherapy treatment.
Postoperative nausea and vomiting (PONV) occurs in 80% of high-risk patients following surgery as a result of anesthesia and/or the pain medications given during their operation. PONV can have serious side effects, including dehydration, electrolyte imbalance, and increased blood pressure, and can require longer hospital stays.
About Galena Biopharma
Galena Biopharma, Inc. (NASDAQ:GALE) is a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax(TM) (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company's commercial drugs include Abstral(R) (fentanyl) Sublingual Tablets and Zuplenz(R) (ondansetron) Oral Soluble Film. Collectively, Galena's clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to improve cancer care, from direct treatment of the disease to the reduction of its debilitating side-effects. For more information, visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the progress of the commercialization of Zuplenz(R) and development of Galena's product candidates, including patient enrollment in our clinical trials, as well as statements about our expectations, plans and prospects. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under "Risk Factors" in Galena's Annual Report on Form 10-K for the year ended December 31, 2014 and most recent Quarterly Reports on Form 10-Q filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.
Abstral and NeuVax are trademarks of Galena Biopharma, Inc. All other trademarks are the property of their respective owners, and Zuplenz is licensed by Galena Biopharma, Inc.
CONTACT: Remy Bernarda
SVP, Investor Relations & Corporate Communications
(503) 405-8258
rbernarda@galenabiopharma.com
(MORE TO FOLLOW) Dow Jones Newswires
July 29, 2015 07:05 ET (11:05 GMT)
Then why are you looking at and posting on a message board for one? lol
Added again at .24 today!
Getting everything at bargain basement prices lately! Loving it!
Loving this pps, nice value! Adding more every time it dips, accumulating a LOT of shares! lol
GLTA
Bought back in at .0202 today, couldn't resist!
I'll buy additional blocks every tenth of a penny under .02!
GLTA